Vicarius Pharma is a newly launched Swiss company providing U.S.-based biopharmaceutical companies a novel approach to commercializing their first asset in European markets. The company acts as an innovator’s go-to-market organization in Europe, building customer-facing commercial teams, holding marketing authorization, and taking legal and operational responsibility while absorbing launch costs. Its value-sharing partnership model enables innovators to retain strategic control over R&D and to recover the asset and the dedicated organization built by Vicarius at any time. Vicarius offers strategic advice on regulatory, pricing, and commercial strategy and focuses on specialty, rare disease, and hospital products. The executive team is led by CEO Hans Peter Hasler, and James C. Mullen is an investor and serves as executive chairman of the board. Financially, Vicarius secured CHF21 million (approximately $21.8 million) in a Series A preferred stock financing from private investors.

Total raised

$22M

Funding rounds

1

Latest round

Series A

Latest activity

Aug 2017